In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Defensive lineman Desmond Watson shed 26 pounds in less than a month, but if selected in the NFL draft would still be ...

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going ...

El director ejecutivo de PepsiCo Inc., Ramón Laguarta, está acostumbrado a que le pregunten sobre el impacto de los exitosos ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...